The new drug research led by Professor Lu Shun from Shanghai Chest Hospital was published in the international authoritative academic journal JCO

On March 13, a research team led by professor Lu Shun, director of the Oncology department of the affiliated Chest Hospital, published the latest research results online in the Journal of Clinical Oncology, the official Journal of the American society of Clinical Oncology: “Evaluation for joint‘s best ketoneses support therapy in the second line standard chemotherapy failure of patients with squamous cell non-small cell lung cancer late curative effect and safety of the Randomized, double-blind, placebo-controlled, multicenter phase II clinical studies (Randomized, Double Blind, Placebo Controlled, MulticenterPhase II Study of Fruquintinib After Two Prior Chemotherapy Regimens in ChinesePatients With Advanced Nonsquamous Non - Small Cell Lung Cancer), ”impact factor (IF) of 24.008. Professor Lu Shun is the first author and corresponding author of the paper. 

Shanghai Chest Hospitals have always attached great importance to clinical research, and in recent years, they have strongly supported various types of clinical research projects with clinical transformation value. The publication of professor Lu Shun’s research results shows the breakthrough made by the hospital in the clinical research of lung cancer drugs, marking a new high in the level of clinical research in the hospital.

 Cefuroxime quetiapine is by the independent research and development in our country, with completely independent intellectual property rights of national first class anti-tumor vascular drugs, are used in colon cancer and so on the many kinds of tumor treatment, while it is the first timein the late than squamous cell non-small cell lung cancer treatment field study. The study compares the cefuroxime quetiapine for best support, joint progression-free surialversus placebo treatment, conducts evaluation of objective response rate of two groups of patients, disease control rates and survival as well as the safety and tolerability, to detect failure for Nepal for multi-line ketoneses therapy preliminary efficacy and benefit of end-stage cancer patients obviously. 

A total of 91 patients were randomly enrolled in 12 centers in this clinical study, 61 of whom were treated with furquintini and 30 with placebo. The median progression-free survival time was 3.8 months in the fuquitinib group and 1.1 months in the placebo group. The survival rates of the fuquitinib group at 3 months and 6 months were 90.2% and 67.2%, while those of the placebo group were 73.3% and 58.8%, respectively. The results showed that furquinolinib was safe and effective in the treatment of advanced NSCLC. This result provides an effective drug treatment option for patients without a standard regimen of third-line chemotherapy.